-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Erfonrilimab in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Erfonrilimab in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Erfonrilimab in Gastric Cancer Drug Details: KN-046 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Erfonrilimab in Gastroesophageal (GE) Junction Carcinomas
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Erfonrilimab in Gastroesophageal (GE) Junction Carcinomas report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Erfonrilimab in Gastroesophageal (GE) Junction Carcinomas Drug Details: KN-046...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Erfonrilimab in Thymic Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Erfonrilimab in Thymic Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Erfonrilimab in Thymic Carcinoma Drug Details: KN-046 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BP-1002 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BP-1002 in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Peripheral T-Cell Lymphomas (PTCL) Drug Details: BP-1002...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BP-1002 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Relapsed Acute Myeloid Leukemia Drug Details: BP-1002...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BP-1002 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Refractory Acute Myeloid Leukemia Drug Details: BP-1002...
-
Thematic Analysis
NewSharing Economy – Thematic Intelligence
Sharing Economy Thematic Intelligence Report Overview The sharing economy is an economic system in which private individuals share assets and services, either free or for a charge often using a community-based online platform. Individuals can share assets such as clothes and toys or services such as household skills and insurance. The sharing economy is based on ideas of community as the world grows ever more interconnected. As the sharing economy model reaches maturity, market players are harnessing technologies such as...
-
Sector Analysis
Automotive Connected Vehicle Technologies Market Trends, Sector Overview and Forecast to 2028
Automotive Connected Vehicle Technologies Market Overview The connected technologies market size was 48.2 million units in 2023. The market will grow at a CAGR of more than 5% during 2023-2028. Advanced diagnostic systems will promote connected car technology market growth. With modern diagnostics, the car's system will provide information about the vehicle to the auto shop and the customers. This will help them identify future problems with the car before they arise and enable customers to take charge of their...
-
Sector Analysis
France Cards and Payments – Opportunities and Risks to 2028
France Cards and Payments Market Overview The annual value of card transactions in the France cards and payments market was $857.59 billion in 2023. The French cards and payments industry is well developed. Multi-functional cards are a prominent feature of the French payment card market. The most common combination is debit and charge card facilities via a single payment card. Additionally, the growing adoption of contactless cards, the expansion of digital-only banks, the emergence of alternative payment solutions, and the...